SAN FRANCISCO, June 2 /PRNewswire/ -- Sofinnova Ventures, a San Francisco venture firm investing in early-stage life science and information technology companies, announced today that Jeffrey Stein, Ph.D. has joined the firm as a life science venture partner and Kauffman Fellow. Stein will work with Sofinnova's life science investment team to identify San Diego-based investment opportunities in the area of biopharmaceutical clinical development, and advise the firm's life science portfolio companies on clinical and business matters. Stein has held senior scientific and management positions in the biopharmaceutical industry for the past 12 years. Previously he was a founder, Director and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer in 2004. Prior to founding Quorex, Stein was Principal Scientist at Diversa Corporation. He was also a Principal Investigator at the Agouron Institute, where his group pioneered the cloning and expression of multi-gene small molecule pathways. Stein currently consults for UC San Diego in venture development and technology spin-outs and will continue in this role. "Sofinnova is a compelling opportunity for me because of the firm's strong track record in both the biotechnology and information technology industries, and because the partners are so highly regarded by their peers," said Stein. "In addition, as a Kauffman Fellow I felt that the compact, experienced team of investment professionals at Sofinnova would provide an ideal dynamic for me to make near-term contributions. I feel very fortunate to be associated with this team." "Jeff's excellent scientific and entrepreneurial backgrounds will posture him to provide real value to Sofinnova's life science portfolio companies," commented Mike Powell, Ph.D., Managing Director at Sofinnova Ventures. "He'll be a strategic asset to Sofinnova as well, because he's well-positioned to identify some of the significant biopharmaceutical investment opportunities in San Diego, a region rich with scientific innovation." Stein received his Ph.D. from the University of California, San Diego as a NASA Fellow and conducted postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at Caltech. Among the various honors Stein has received is the Thomas Alva Edison Patent Award. He currently serves on the board of Rx3 Pharmaceuticals. About Sofinnova Ventures Sofinnova Ventures is a venture capital firm emphasizing a diversified investment strategy through financing early stage companies in the life science and information technology sectors. Founded in 1974, the San Francisco-based firm currently has $600 million under management. Sofinnova's mission is to create value by providing entrepreneurs with the resources, experience and networks necessary to turn their bright ideas into thriving businesses. With deeply rooted ties to Europe's leading financial, technology and venture institutions, Sofinnova is also uniquely positioned to foster trans-Atlantic synergy and market acceleration. For more information, visit www.sofinnova.com.
SOURCE Sofinnova Ventures